486 related articles for article (PubMed ID: 23910578)
1. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
Antunes SV; Tangada S; Stasyshyn O; Mamonov V; Phillips J; Guzman-Becerra N; Grigorian A; Ewenstein B; Wong WY
Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study.
Stasyshyn O; Antunes S; Mamonov V; Ye X; Epstein J; Xiong Y; Tangada S
Haemophilia; 2014 Sep; 20(5):644-50. PubMed ID: 24589084
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors.
Ewing N; Escuriola-Ettingshausen C; Kreuz W
Haemophilia; 2015 May; 21(3):358-364. PubMed ID: 25603840
[TBL] [Abstract][Full Text] [Related]
4. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
Valentino LA
Haemophilia; 2010 Mar; 16(2):263-71. PubMed ID: 20028421
[TBL] [Abstract][Full Text] [Related]
5. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations.
Perry D; Berntorp E; Tait C; Dolan G; Holme PA; Laffan M; Lassila R; Mumford A; Pasi J; Wilde J; Will A; Yee TT
Haemophilia; 2010 Jan; 16(1):80-9. PubMed ID: 19780845
[TBL] [Abstract][Full Text] [Related]
6. A retrospective postlicensure survey of FEIBA efficacy and safety.
Dimichele D; Négrier C
Haemophilia; 2006 Jul; 12(4):352-62. PubMed ID: 16834734
[TBL] [Abstract][Full Text] [Related]
7. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
[TBL] [Abstract][Full Text] [Related]
8. Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.
Olasupo OO; Lowe MS; Krishan A; Collins P; Iorio A; Matino D
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014201. PubMed ID: 34407214
[TBL] [Abstract][Full Text] [Related]
9. FEIBA in the treatment of acquired haemophilia A: results from the prospective multicentre French 'FEIBA dans l'hémophilie A acquise' (FEIBHAC) registry.
Borg JY; Négrier C; Durieu I; Dolimier E; Masquelier AM; Lévesque H;
Haemophilia; 2015 May; 21(3):330-337. PubMed ID: 25359571
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.
Valentino LA; Mamonov V; Hellmann A; Quon DV; Chybicka A; Schroth P; Patrone L; Wong WY;
J Thromb Haemost; 2012 Mar; 10(3):359-67. PubMed ID: 22212248
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis in haemophilia with inhibitors: update from international experience.
Carcao M; Lambert T
Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
[TBL] [Abstract][Full Text] [Related]
12. FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre.
Smejkal P; Brabec P; Matyskova M; Bulikova A; Slechtova M; Kissova J; Chlupova G; Muzik J; Penka M
Haemophilia; 2009 May; 15(3):743-51. PubMed ID: 19432925
[TBL] [Abstract][Full Text] [Related]
13. The current status of prophylactic replacement therapy in children and adults with haemophilia.
Ljung R; Gretenkort Andersson N
Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
[TBL] [Abstract][Full Text] [Related]
14. FEIBA safety profile in multiple modes of clinical and home-therapy application.
Luu H; Ewenstein B
Haemophilia; 2004 Sep; 10 Suppl 2():10-6. PubMed ID: 15385041
[TBL] [Abstract][Full Text] [Related]
15. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
Villarrubia R; Oyagüez I; Álvarez-Román MT; Mingot-Castellano ME; Parra R; Casado MA
Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.
Ljung R; Auerswald G; Benson G; Dolan G; Duffy A; Hermans C; Jiménez-Yuste V; Lambert T; Morfini M; Zupančić-Šalek S; Santagostino E
Eur J Haematol; 2019 Feb; 102(2):111-122. PubMed ID: 30411401
[TBL] [Abstract][Full Text] [Related]
17. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX.
Tjønnfjord GE; Brinch L; Gedde-Dahl T; Brosstad FR
Haemophilia; 2004 Mar; 10(2):174-8. PubMed ID: 14962207
[TBL] [Abstract][Full Text] [Related]
18. [Prophylaxis in patients with haemophilia complicated by inhibitors].
Paweł Ł
Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
[TBL] [Abstract][Full Text] [Related]
19. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies.
Négrier C; Lienhart A; Numerof R; Stephens D; Wong WY; Baghaei F; Yee TT
Haemophilia; 2013 May; 19(3):e143-50. PubMed ID: 23282031
[TBL] [Abstract][Full Text] [Related]
20. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.
Leissinger C; Gringeri A; Antmen B; Berntorp E; Biasoli C; Carpenter S; Cortesi P; Jo H; Kavakli K; Lassila R; Morfini M; Négrier C; Rocino A; Schramm W; Serban M; Uscatescu MV; Windyga J; Zülfikar B; Mantovani L
N Engl J Med; 2011 Nov; 365(18):1684-92. PubMed ID: 22047559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
